Vistagen Therapeutics (VTGN) Earning Somewhat Positive News Coverage, Report Shows

News coverage about Vistagen Therapeutics (NASDAQ:VTGN) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Vistagen Therapeutics earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.5595298954071 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Vistagen Therapeutics (VTGN) traded down $0.01 on Friday, hitting $1.18. The stock had a trading volume of 165,234 shares, compared to its average volume of 533,944. The company has a market cap of $27.25, a price-to-earnings ratio of -0.86 and a beta of -1.31. Vistagen Therapeutics has a 1-year low of $0.69 and a 1-year high of $2.75.

Vistagen Therapeutics (NASDAQ:VTGN) last released its quarterly earnings data on Monday, February 12th. The company reported ($0.24) earnings per share for the quarter. equities research analysts forecast that Vistagen Therapeutics will post -1.89 earnings per share for the current fiscal year.

Separately, Chardan Capital reduced their price objective on Vistagen Therapeutics from $30.00 to $22.00 and set a “buy” rating for the company in a research note on Thursday, February 8th.

ILLEGAL ACTIVITY NOTICE: “Vistagen Therapeutics (VTGN) Earning Somewhat Positive News Coverage, Report Shows” was originally published by Transcript Daily and is owned by of Transcript Daily. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at

Vistagen Therapeutics Company Profile

VistaGen Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants approved by the United States Food and Drug Administration (FDA).

Insider Buying and Selling by Quarter for Vistagen Therapeutics (NASDAQ:VTGN)

Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply